A Retrospective Analysis: the Influence of Caltrate Supplement on the Effect of Mesalazine in Ulcerative Colitis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

74 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-01

Study Completion Date

2021-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aims:Retrospectively observe the effects of Caltrate supplementation on the clinical effect of mesalazine in patients with ulcerative colitis.

Design: From January 2015 to December 2020, through retrieving the clinical database of the Second Affiliated Hospital of Wenzhou Medical University, patients with active UC who accepted mesalazine treatment were enrolled. According to whether Caltrate was supplemented at the same time, the patients were divided into supplementary group and non-supplementary group. The modified Mayo score and several laboratory indicators were compared between the two groups.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Vitamin D Supplementation on Vedolizumab Response in Patients With Ulcerative Colitis

NCT05649462

Ulcerative Colitis Vitamin D Deficiency Vitamin D Supplement

COMPLETED

Exploring the Effects of Caltrate Supplement on the Chronic Course of Crohn's Disease Patients With Vitamin D Deficiency

NCT04276636

Crohn's Disease Vitamin D Deficiency Vitamin D Supplement

UNKNOWN EARLY_PHASE1

Observation of the Effect of Vitamin D Supplementation on Chronic Course of Patients With Ulcerative Colitis Based on Vitamin D Receptor Fok I Gene Polymorphism

NCT04309058

Ulcerative Colitis Vitamin D Deficiency Vitamin D Supplement

UNKNOWN EARLY_PHASE1

Effect and Mechanism of Dopamine on Ulcerative Colitis

NCT05214404

Dopamine Dysregulation Syndrome Ulcerative Colitis

COMPLETED

Vitamin D Treatment in Ulcerative Colitis

NCT01640496

Ulcerative Colitis Inflammatory Bowel Disease

WITHDRAWN NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

1. The research has been approved by the Medical Ethics Committee of the Second Affiliated Hospital of Wenzhou Medical University.
2. According to the "Consensus on Diagnosis and Treatment of Inflammatory Bowel Disease" formulated by the Beijing Conference in 2018 as a standard, patients with clear diagnosis of UC are collected. Exclusion criteria included: history of vitamin D treatment within the previous 3 months; treated with glucocorticoids, immunosuppressants, biologic agents, or colectomy during the follow-up; severe liver and kidney dysfunction; other autoimmune diseases.
3. Assess disease activity of UC participants based on the "Mayo score".
4. General information about participants with UC is collected.
5. Serum C-reactive protein, erythrocyte sedimentation rate, white blood cells, albumin, creatinine, calcium and phosphorus levels are measured.
6. The level of serum 25 (OH) D of participants is detected.
7. Participants are divided into two groups, one group was given oral Caltrate 0.6g/d +Mesalazine, and the other group only took Mesalazine .
8. The above serum indicators are re-measured in the 12th month, and the condition of UC participants is also evaluated.
9. Follow-up for 12 months. By comparing the above indicators, observe that in the Han population:

1. Can Caltrate supplementation increase serum 25 (OH) D levels in patients with UC?
2. Can Caltrate supplementation improve the condition of patients with UC?
3. Whether Caltrate works synergistically with Mesalazine?
4. whether the effect of Caltrate on UC patients is affected by factors such as disease site, disease activity, treatment, etc ..
10. Through statistical analysis, comprehensive analysis of the effectiveness and safety of Caltrate supplementation in Han patients with UC, providing a theoretical basis for further "precise treatment" intervention in inflammatory bowel disease.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Ulcerative Colitis Vitamin D Deficiency Vitamin D Supplement

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Caltrate+Mesalazine

Patients in this group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months.

Caltrate

Intervention Type DRUG

Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.

Mesalazine

Patients in this group were received with Mesalazine 4g/d orally at least 12 months.

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Caltrate

Patients in supplementary group were received with Caltrate 0.6 g/d and Mesalazine 4g/d orally at least 12 months, and those in non-supplementary only take Mesalazine 4g/d.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Clearly diagnosed patients with UC
* Took mesalazine for at least 12 months

Exclusion Criteria

* had recent supplementation of vitD3
* had prior or concomitant use of other biologic agent, glucocorticoid and/or immunomodulators at the time of enrollment or follow up
* Co-morbid with other autoimmune diseases
* Severe liver and kidney dysfunction

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No